We are live on ! Find out more
OFIX icon

Orthofix Medical

130 hedge funds and large institutions have $472M invested in Orthofix Medical in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 43 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

5% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 43

0.85% less ownership

Funds ownership: 95.62%94.77% (-0.85%)

4% less funds holding

Funds holding: 136130 (-6)

9% less capital invested

Capital invested by funds: $519M → $472M (-$47.8M)

15% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 27

97% less call options, than puts

Call options by funds: $10K | Put options by funds: $296K

Holders
130
Holders Change
-6
Holders Change %
-4.41%
% of All Funds
1.88%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
23
Increased
45
Reduced
43
Closed
27
Calls
$10K
Puts
$296K
Net Calls
-$286K
Net Calls Change
-$251K
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$49.7M +$685K +50,000 +1%
RCMNY
2
Rubric Capital Management (New York)
New York
$49M +$410K +29,946 +0.8%
ECM
3
Engine Capital Management
New York
$44.7M +$4.57M +333,364 +11%
BlackRock
4
BlackRock
New York
$42.3M -$1.46M -106,420 -3%
PCMI
5
Paradigm Capital Management Inc
New York
$33.9M +$8.35M +609,137 +31%
Vanguard Group
6
Vanguard Group
Pennsylvania
$27.6M +$978K +71,399 +4%
Morgan Stanley
7
Morgan Stanley
New York
$26.8M -$10.1M -737,096 -27%
NM
8
Newtyn Management
New York
$22.1M +$5.43M +396,215 +31%
GCM
9
Glenview Capital Management
New York
$14.7M +$3.04M +221,928 +25%
State Street
10
State Street
Massachusetts
$12M -$2.18M -159,416 -15%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$11M +$302K +22,049 +3%
BCM
12
Boone Capital Management
Georgia
$10.3M -$2.73M -199,134 -20%
EA
13
Emerald Advisers
Pennsylvania
$9.73M -$428K -31,205 -4%
ACA
14
AYAL Capital Advisors
Ontario, Canada
$9.11M +$873K +63,697 +10%
AIC
15
AWM Investment Company
New York
$5.96M -$343K -25,000 -5%
TC
16
Tejara Capital
United Kingdom
$5.76M
EMFAT
17
Emerald Mutual Fund Advisers Trust
Pennsylvania
$5.23M
Millennium Management
18
Millennium Management
New York
$5.21M -$561K -40,927 -9%
Northern Trust
19
Northern Trust
Illinois
$4.63M -$54K -3,939 -1%
Citadel Advisors
20
Citadel Advisors
Florida
$4.4M +$1.66M +120,986 +57%
JIC
21
Juniper Investment Company
New York
$4.1M +$4.24M +309,285 New
Charles Schwab
22
Charles Schwab
California
$3.78M +$17.6K +1,284 +0.5%
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$3.73M -$839K -61,239 -18%
N
24
Nuveen
North Carolina
$3.67M +$920K +67,109 +32%
GLA
25
Great Lakes Advisors
Illinois
$3.44M +$467K +34,114 +15%

OFIX Hedge Fund Activity: Q2 2024 in Review

130 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Orthofix Medical (OFIX) for Q2 2024, worth a combined $472M — down 9.2% from $519M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of OFIX and 23 opened new positions — a net loss of 4 holders — while 43 trimmed existing stakes and 45 added.

The largest buyer was Paradigm Capital Management Inc, adding an estimated $8.35M. The largest seller was Morgan Stanley, cutting an estimated $10.1M.

  • 130 institutional investors held Orthofix Medical (OFIX) as of Q2 2024, down from 136 in Q1 2024.
  • Funds reported $472M of Orthofix Medical stock for Q2 2024, down 9.2% quarter-over-quarter.
  • 23 funds opened new Orthofix Medical positions in Q2 2024 and 27 closed out, a net change of -4 holders.
  • The largest Orthofix Medical buyer in Q2 2024 was Paradigm Capital Management Inc, an estimated $8.35M added.
  • The largest Orthofix Medical seller in Q2 2024 was Morgan Stanley, an estimated $10.1M sold.

Based on aggregated 13F filings for Q2 2024.